ロード中...
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for effi...
保存先:
| 出版年: | J Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ivyspring International Publisher
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5370494/ https://ncbi.nlm.nih.gov/pubmed/28367230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.17644 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|